Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q1 2024 · 10-Q
Revenue$174.74M$174.74M−49.9% vs Q1 2023 Net Income$8.32M$8.32M−79.2% vs Q1 2023 EPS Diluted$0.76$0.76−79.3% vs Q1 2023 Gross Profit$127,292,000−48.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flow$7,282,000−88.6% Free Cash Flowderived$5,441,000−91.2% Margins · derivedGross margin72.8%+2.2 pt vs Q1 2023
Operating margin4.5%−10.8 pt vs Q1 2023
Net margin4.8%−6.7 pt vs Q1 2023
ended Mar 31, 2024 · filed Apr 29, 2024 · 29 d after period end